Avodart® is the new medication from GlaxoSmithKline for reducing DHT. Dihydrotestosterone (DHT) is the main hormone linked to hairloss. Propecia® prevents one of two enzymes from being converted into DHT and blocks 2/3 of the DHT production. The new medication Avodart® blocks both enzymes in the body that convert into DHT and reduces overall DHT production by over 93%.
Avodart® comes in a 0.5mg softgel capsule that is taken by mouth once per day.
Propecia was originally approved under the name Proscar® for BPH and was only released for hair loss years later. Avodart has been approved for the treatment of Benign Prostatic Hyperplasia (BPH, or enlarged prostates) and is currently under study for approval for hair loss.
Avodart® at this dosage reduced DHT by 93.1-93.6% after 12-months on the medication. Scalp DHT was decreased 38% for Propecia®/Finasteride compared to 54% for 0.5mg Dutasteride.
Since Avodart® is currently being studied for hair loss, there are no exact figures on the percent of responders or results other than some of the sample photos released by the company from the studies. Results are expected to surpass Propecia's.
Our Avodart® is the original brand-name Avodart® 0.5mg from GlaxoSmithKline in the United States and is not a generic or international formulation.
Avodart® is not tested or approved for women and should not under any circumstances be taken by women who may become pregnant.
| 
